This session explores how near-infrared spectroscopy (NIRS) is redefining PCI by revealing what angiography cannot see. By identifying lipid-rich and vulnerable plaques, NIRS helps anticipate procedural risk and refine decision-making before stent implantation. The session shows how plaque composition, rather than calcium alone, can guide lesion...

At the ESC Congress 2019 in Paris, Jean-François Obadia presented the results of the 2 years follow-Up of the MITRA-FR study. Read the report by Nicole Karam.

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...